SLC25A42 promotes gastric cancer growth by conferring ferroptosis resistance through enhancing CPT2-mediated fatty acid oxidation

Abstract Accumulating evidence has shown that the dysfunction of mitochondria, the multifunctional organelles in various cellular processes, is a pivotal event in the development of various diseases, including human cancers. Solute Carrier Family 25 Member 42 (SLC25A42) is a mitochondrial protein go...

Full description

Saved in:
Bibliographic Details
Main Authors: Haoying Wang, Weijia Dou, Mengxiao Liu, Weifang Wang, Ying Yang, Jibin Li, Zhenxiong Liu, Nan Wang
Format: Article
Language:English
Published: Nature Publishing Group 2025-04-01
Series:Cell Death and Disease
Online Access:https://doi.org/10.1038/s41419-025-07644-7
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849700057361678336
author Haoying Wang
Weijia Dou
Mengxiao Liu
Weifang Wang
Ying Yang
Jibin Li
Zhenxiong Liu
Nan Wang
author_facet Haoying Wang
Weijia Dou
Mengxiao Liu
Weifang Wang
Ying Yang
Jibin Li
Zhenxiong Liu
Nan Wang
author_sort Haoying Wang
collection DOAJ
description Abstract Accumulating evidence has shown that the dysfunction of mitochondria, the multifunctional organelles in various cellular processes, is a pivotal event in the development of various diseases, including human cancers. Solute Carrier Family 25 Member 42 (SLC25A42) is a mitochondrial protein governing the transport of coenzyme A (CoA). However, the biological roles of SLC25A42 in human cancers are still unexplored. Here we uncovered that SLC25A42 is upregulated and correlated with a worse prognosis in GC patients. SLC25A42 promotes the proliferation of gastric cancer (GC) cells while suppresses apoptosis in vitro and in vivo. Mechanistically, SLC25A42 promotes the growth and inhibits apoptosis of GC cells by reprograming lipid metabolism. On the one hand, SLC25A42 enhances fatty acid oxidation-mediated mitochondrial respiration to provide energy for cell survival. On the other hand, SLC25A42 decreases the levels of free fatty acids and ROS to inhibit ferroptosis. Moreover, we found that SLC25A42 reprograms lipid metabolism in GC cells by upregulating the acetylation and thus the expression of CPT2. Collectively, our data reveal a critical oncogenic role of SLC25A42 in GCs and suggest that SLC25A42 represent a promising therapeutic target for GC.
format Article
id doaj-art-9b5f68dc39054559b0ebe8a975325c50
institution DOAJ
issn 2041-4889
language English
publishDate 2025-04-01
publisher Nature Publishing Group
record_format Article
series Cell Death and Disease
spelling doaj-art-9b5f68dc39054559b0ebe8a975325c502025-08-20T03:18:23ZengNature Publishing GroupCell Death and Disease2041-48892025-04-0116111210.1038/s41419-025-07644-7SLC25A42 promotes gastric cancer growth by conferring ferroptosis resistance through enhancing CPT2-mediated fatty acid oxidationHaoying Wang0Weijia Dou1Mengxiao Liu2Weifang Wang3Ying Yang4Jibin Li5Zhenxiong Liu6Nan Wang7Department of Gastroenterology, Tangdu Hospital, The Air Force Medical UniversityDepartment of Gastroenterology, Tangdu Hospital, The Air Force Medical UniversityDepartment of Gastroenterology, Xijing Hospital, The Air Force Medical UniversityState Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers and Department of Physiology and Pathophysiology, The Air Force Medical UniversityDepartment of General Surgery, Tangdu Hospital, The Air Force Medical UniversityState Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers and Department of Physiology and Pathophysiology, The Air Force Medical UniversityDepartment of Gastroenterology, Tangdu Hospital, The Air Force Medical UniversityDepartment of General Surgery, Tangdu Hospital, The Air Force Medical UniversityAbstract Accumulating evidence has shown that the dysfunction of mitochondria, the multifunctional organelles in various cellular processes, is a pivotal event in the development of various diseases, including human cancers. Solute Carrier Family 25 Member 42 (SLC25A42) is a mitochondrial protein governing the transport of coenzyme A (CoA). However, the biological roles of SLC25A42 in human cancers are still unexplored. Here we uncovered that SLC25A42 is upregulated and correlated with a worse prognosis in GC patients. SLC25A42 promotes the proliferation of gastric cancer (GC) cells while suppresses apoptosis in vitro and in vivo. Mechanistically, SLC25A42 promotes the growth and inhibits apoptosis of GC cells by reprograming lipid metabolism. On the one hand, SLC25A42 enhances fatty acid oxidation-mediated mitochondrial respiration to provide energy for cell survival. On the other hand, SLC25A42 decreases the levels of free fatty acids and ROS to inhibit ferroptosis. Moreover, we found that SLC25A42 reprograms lipid metabolism in GC cells by upregulating the acetylation and thus the expression of CPT2. Collectively, our data reveal a critical oncogenic role of SLC25A42 in GCs and suggest that SLC25A42 represent a promising therapeutic target for GC.https://doi.org/10.1038/s41419-025-07644-7
spellingShingle Haoying Wang
Weijia Dou
Mengxiao Liu
Weifang Wang
Ying Yang
Jibin Li
Zhenxiong Liu
Nan Wang
SLC25A42 promotes gastric cancer growth by conferring ferroptosis resistance through enhancing CPT2-mediated fatty acid oxidation
Cell Death and Disease
title SLC25A42 promotes gastric cancer growth by conferring ferroptosis resistance through enhancing CPT2-mediated fatty acid oxidation
title_full SLC25A42 promotes gastric cancer growth by conferring ferroptosis resistance through enhancing CPT2-mediated fatty acid oxidation
title_fullStr SLC25A42 promotes gastric cancer growth by conferring ferroptosis resistance through enhancing CPT2-mediated fatty acid oxidation
title_full_unstemmed SLC25A42 promotes gastric cancer growth by conferring ferroptosis resistance through enhancing CPT2-mediated fatty acid oxidation
title_short SLC25A42 promotes gastric cancer growth by conferring ferroptosis resistance through enhancing CPT2-mediated fatty acid oxidation
title_sort slc25a42 promotes gastric cancer growth by conferring ferroptosis resistance through enhancing cpt2 mediated fatty acid oxidation
url https://doi.org/10.1038/s41419-025-07644-7
work_keys_str_mv AT haoyingwang slc25a42promotesgastriccancergrowthbyconferringferroptosisresistancethroughenhancingcpt2mediatedfattyacidoxidation
AT weijiadou slc25a42promotesgastriccancergrowthbyconferringferroptosisresistancethroughenhancingcpt2mediatedfattyacidoxidation
AT mengxiaoliu slc25a42promotesgastriccancergrowthbyconferringferroptosisresistancethroughenhancingcpt2mediatedfattyacidoxidation
AT weifangwang slc25a42promotesgastriccancergrowthbyconferringferroptosisresistancethroughenhancingcpt2mediatedfattyacidoxidation
AT yingyang slc25a42promotesgastriccancergrowthbyconferringferroptosisresistancethroughenhancingcpt2mediatedfattyacidoxidation
AT jibinli slc25a42promotesgastriccancergrowthbyconferringferroptosisresistancethroughenhancingcpt2mediatedfattyacidoxidation
AT zhenxiongliu slc25a42promotesgastriccancergrowthbyconferringferroptosisresistancethroughenhancingcpt2mediatedfattyacidoxidation
AT nanwang slc25a42promotesgastriccancergrowthbyconferringferroptosisresistancethroughenhancingcpt2mediatedfattyacidoxidation